Navigation Links
New type of genetic change identified in inherited cancer
Date:10/4/2009

DURHAM, N.C. Duke University Medical Center and National Cancer Institute scientists have discovered that a novel genetic alteration a second copy of an entire gene is a cause of familial chordoma, an uncommon form of cancer arising in bones and frequently affecting the nervous system.

Inherited differences in gene copy number, known as copy number variation (CNV), have been implicated in some hereditary diseases but none of the previously discovered familial cancer genes has had CNV as the genetic change.

"This alteration is unlike anything we have ever seen before in families that tend to develop the same kind of cancers," says Michael Kelley, M.D., an associate professor at Duke University Medical Center and senior author of the study appearing in Nature Genetics. "We are not talking about a mutation in a single gene, but the duplication of an entire gene. This discovery is a classic example of where science answers one question but raises many, many more."

Chordoma is rare, striking only one in every million people. But it is a devastating diagnosis. People who have the disorder typically develop tumors at the base of the skull, in the pelvis, or along the spinal column. The growths are thought to arise from remnants of the notochord, an embryonic precursor to spinal column. There are few treatments and no cure for chordoma; most who have the disease usually die within 10 years.

Kelley, chief of hematology and oncology at the Durham Veterans Affairs Medical Center, has been studying chordoma for years after a collaborator at the National Cancer Institute, Dilys Parry, a co-author of the study, discovered a family with a history of the disease spanning several generations. They concluded that there had to be some sort of inherited genetic defect at work. Parry conducted clinical studies that eventually identified six additional families with multiple relatives with chordoma.

Initial work focused on possible defects on chromosome 7, but no defect was found that was shared by all of those affected. Researchers conducted linkage studies that revealed six new areas in the genome where potential mutations were likely. But it wasn't until they used a technique called array comparative genomic hybridization, a method that allowed them to see structural changes in the genome in exquisite detail, that they were able to pinpoint the source of the culprit. They identified it as the T (Brachyury) gene on chromosome 6.

"Brachyury is a transcription factor that helps regulate the development of the notochord and we know the gene is overly active in the tumor tissue in many people with chordoma," says Kelley, "so we were pretty sure we were on to something."

Investigators screened 65 individuals (21 with chordoma) in seven families with a history of the disease, specifically looking for any alterations in the T gene. They discovered that all the patients with chordoma in four of the seven families had a second copy of the T gene. The duplication did not appear among members of the three other families, nor did it appear in 100 healthy, normal controls.

Kelley says investigators do not understand what Brachyury does to cause chordoma. Brachyury expression was found in tissue from chordomas not only in patients who had inherited the duplication but also in those who did not have the duplication.

"It is likely that other genes are at work here, or that some other mechanism we do not yet understand is in play. Based on our research, however, we do feel that it may be worthwhile to screen for complex genomic rearragements when trying to find the cause of familial cancers. It may be a more productive route than traditional gene-mapping methods."

Xiaohong Yang of the National Cancer Institute wrote the first draft of the paper, and along with David Ng, also of the NCI, analyzed the data. Ng, Sufeng Li, Kelly and David Alcorta, all of Duke, performed the laboratory studies including genotyping, sequencing and breakpoint evaluation. Parry, Ng, Eamonn Sheridan of St. James Hospital in Leeds, UK, and Norbert Liebsch, from Massachusetts General Hospital, identified and evaluated the chordoma families. Yang, Ng, Kelley, Parry and Alisa Goldstein planned the work and interpreted the results.


'/>"/>

Contact: Michelle Gailiun
michelle.gailiun@duke.edu
919-660-1306
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Many Parents Share Genetic Test Findings With Kids
2. Genetic predisposition increases childhood asthma risk
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Test Spots Genetic Damage Done by Smoking
5. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
6. Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
7. Genetics Hold Promise, Challenges for Cancer Care
8. Researchers genetically engineer micro-organisms into tiny factories
9. Study Questions Genetic Screening for Treatable Diseases
10. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
11. Genetic variation affects smoking cessation treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and ... the ultimate weight loss and wellness program, at their world headquarters of Omni La ... immediate and long-term results to anyone seeking weight loss, personal development, a healthy lifestyle, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... continuity to its innovative Unified Instance Manager architecture, meeting the needs of ... new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides ...
(Date:12/8/2016)... ... 08, 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 ... the highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) ... Dr. Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into law ... in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition ... to the study, medical payments per claim in California decreased 4 percent in 2013 ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Henry Schein, Inc. (Nasdaq: ... care products and services to office-based dental, animal health and ... equity investment in Marrodent, one of Poland,s ... $32 million. This transaction was announced on August 30, 2016. ... Poland since 2014, and Marrodent marks ...
(Date:12/8/2016)... 2016 Research and Markets has announced the addition ... to their offering. ... The report provides separate comprehensive analytics for ... and Rest of World. Annual estimates and forecasts are ... is provided for these markets. Market data and analytics are derived from ...
(Date:12/7/2016)... -- "Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight" report by ... drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially ... Kenya , Czech Republic , ... , Slovakia , United Kingdom ... patent on Lantus expired in 2014. Lantus is the brand name ...
Breaking Medicine Technology: